With a focus on clinical development, regulatory approval, payer coverage and reimbursement, and health economics, the IMPACT Advisory Board is the cornerstone of Freenome’s commitment to broad patient access to multiomics blood tests for the early detection of cancer.
Comprised of leading experts in cancer biology, molecular biology, computational biology, and machine learning, the Scientific Advisory Board (SAB) provides strategic and scientific counsel to advance the development of Freenome’s technology platform and commercial disease screening products.
Freenomers are technical and creative, visionary and grounded, empathetic and passionate. We build teams around divergent expertise, which allows us to solve problems and uncover opportunities in unique ways. Freenomers are some of the most talented experts in their fields. Together we advance healthcare one breakthrough at a time.